Stock Taper 
ADXN
$3.84
▼ DOWN 0.26% (-0.01)
KEY STATISTICS
Market Cap$4.73 M
52w High$12.05
52w Low$3.73
Dividend Yield—
Frequency—
P/E-0.61
Volume21.34K
Shares Out.1.23M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Timothy Mark Dyer
ABOUT
SECTOR
Healthcare
WENT PUBLIC
February 12, 2020
METHOD OF GOING PUBLIC
Dual Listing
FULL TIME EMPLOYEES
3
PRICE TARGET
Target High$30.00
Target Low$30.00
Target Median$30.00
Target Consensus$30.00
UPCOMING EARNINGS
DateNov 9, 2026
DayMonday
Rev. Est.—
NOV
9
MON
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2023-10-23 | Reverse | 1:20 |
PRICE
$3.84 ▼ DOWN 0.26% (−$0.01)About Addex Therapeutics Ltd
https://www.addextherapeutics.com ↗Addex Therapeutics Ltd, a Swiss biopharma, develops small-molecule CNS disorder treatments, including Dipraglurant and ADX71149, through allosteric G-protein coupled receptor modulators, with collaborations involving Janssen, Indivior, and others.
INDUSTRY
Biotechnology
A PRODUCT ADDEX THERAPEUTICS LTD IS KNOWN FOR
GABAB PAM for chronic cough
Addex's clinical-stage GABAB PAM drug candidate for chronic cough has shown preclinical efficacy in reducing cough and is now progressing toward IND-enabling studies.
Revenue by Products
| Icon | PRODUCT | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
 | Research | $2.9M | $1.4M ▼ | $1.6M ▲ | $400K ▼ |
RATINGS SNAPSHOT
Overall rating: B-
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2
INSIDER TRADES
★
DIRECTOR
Lawton Vincent Michael
— · —
2026-03-18
★
OFFICER: PRINCIPAL ACCOUNTING OFFICER
Teyssedou Lenaic Nathanael
— · 90.5K shares
2022-10-05
★
DIRECTOR
Hill Raymond George
— · 273.1K shares
2024-01-08
★
DIRECTOR
Lawton Vincent Michael
— · 501.6K shares
2024-01-08
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 NRSN | $0.42 | COMPARE |
 BCLI | $1.12 | COMPARE |
 QNRX | $6.12 | COMPARE |
 CDIO | $1.85 | COMPARE |
 ADIL | $5.60 | COMPARE |
 TCRT | $1.60 | COMPARE |
 RADX | $2.41 | COMPARE |